Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692280 | PMC |
| http://dx.doi.org/10.1182/bloodadvances.2023011027 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Routine Prophylaxis with Levetiracetam offers no benefit in CD19 CAR-T for LBCL: a Multicenter Propensity-matched Study.
Blood Adv
August 2025
Inserm U1153, Hôpital Saint Louis, 1 avenue Claude Vellefaux, F-75010 Paris, France.
This study aims to evaluate the impact of levetiracetam (LVT) prophylaxis on the incidence and severity of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in patients undergoing anti-CD19 CAR-T therapy for large B-cell lymphoma (LBCL). A propensity score-matched cohort of 254 patients was analyzed, comparing those receiving LVT prophylaxis with those not receiving it in a 1:1 ratio. The results showed no significant difference in the occurrence of ICANS of any grade between the two groups (32.
View Article and Find Full Text PDF[Recommendations on the prevention and management of radiation-induced lung injury from the Association francophone pour les soins oncologiques de support and the Société française de radiothérapie oncologique].
Cancer Radiother
September 2025
Department of Radiation Oncology, Institut de cancérologie de Lorraine, Vandœuvre-lès-Nancy, France.
Purpose: Radiation-induced lung injury is relatively uncommon but disabling, and a dose-limiting factor in thoracic radiotherapy. This complication is mainly encountered following radiotherapy for lung cancers. We provide recommendations for good clinical practice, defining the prevention and management of radiation-induced lung injury.
View Article and Find Full Text PDFMoving Towards the Delivery of Outpatient T-Cell Engaging Therapy for the Management of Multiple Myeloma.
Clin Lymphoma Myeloma Leuk
September 2025
Perlmutter Cancer Center, NYU Langone Health and NYU Grossman School of Medicine, New York, NY.
Bispecific antibodies (BsAbs) and chimeric antigen receptor T-cells (CAR-T) are T-cell engagers (TCEs) becoming increasingly important for treatment of multiple myeloma. The purpose of this paper is to review TCE side effects and their management. In doing so, we will demonstrate that outpatient delivery of TCEs can be safe and advantageous for patients and healthcare systems.
View Article and Find Full Text PDFTocilizumab Prophylaxis for Patients with Multiple Myeloma Treated with Bispecific Antibodies.
Blood Adv
July 2025
Division of Myeloma, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, United States.
Bispecific antibodies for treatment for multiple myeloma are highly effective but commonly cause cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Emerging data indicate that prophylactic tocilizumab may reduce CRS, without impacting efficacy. We administered a single dose of tocilizumab prior to the first dose of bispecific antibodies to 119 patients to determine the impact on CRS in a real-world setting including BCMAxCD3- and GPRC5DxCD3-targeted antibodies.
View Article and Find Full Text PDFCurrent state-of-the-art of immunotherapy in follicular lymphoma.
Expert Rev Hematol
August 2025
Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.
Introduction: The advent of immunotherapy has rapidly changed the treatment landscape of follicular lymphoma (FL).
Areas Covered: Autologous CD19 chimeric antigen receptor - cell (CAR-T) products show unprecedented efficacy in third-line FL but substantial rates of cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS). Bispecific antibodies (BSAB) achieve deep and durable responses in heavily pretreated FL patients with less severe CRS and minimal neurological toxicity.